Loading data for GERN — first visit, this takes a few seconds.
Geron Corporation (GERN)
NasdaqGS: GERN
· Real-Time Price · USD
1.59
+0.06 (3.92%)
At close: Aug 19, 2026, 8:00 PM
Geron Corporation (GERN) Stock Price, Analysis & Data
3.92% (1D)
No data available
| Bid | 1.56 |
| Market Cap | 1.02B |
| Revenue (ttm) | 204.56M |
| Net Income (ttm) | -67.61M |
| Beta | 0.59 |
| EPS (ttm) | -0.11 |
| PE Ratio (ttm) | n/a |
| Forward PE | 39.75 |
| P/B (ttm) | 4.45 |
| P/S (ttm) | 4.99 |
| Earnings Date | May 6, 2026 |
| Ask | 1.76 |
| Volume | 7,704,141 |
| Avg. Volume (20D) | 11,704,980 |
| Open | 1.57 |
| Previous Close | 1.53 |
| Day's Range | 1.52 - 1.59 |
| 52-Week Range | 1.04 - 2.01 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GERN
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 1996
Employees 258
Stock Exchange NasdaqGS
Ticker Symbol GERN
Website https://www.geron.com
Financial Performance
In 2025, Geron's revenue was 183.88M, an increase of 138.83% compared to the previous year's 76.99M. Earnings were -83.5M, a decrease of -52.17%.
Financial StatementsEarnings Surprise
Geron has released their quarterly earnings on Aug 5, 2026:
Geron Corporation is scheduled to release its earnings on May 6, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2